Skip to main content
EnglishEN
European Commission logo print header

Monitoring multidimensional aspects of QUAlity of Life after cancer ImmunoTherapy - an Open smart digital Platform for personalized prevention and patient management

Project description

DEENESFRITPL

Better monitoring of cancer immunotherapy patients

Cancer immunotherapy has helped to significantly advance cancer treatment. However, there remain two main challenges that hinder the path to better health and quality of life for cancer patients after starting immunotherapy. There is a need for predictive markers for immunotherapy-related adverse events as well as information on such patients beyond randomised controlled trials. To address these problems, the EU-funded QUALITOP project aims to develop a European immunotherapy-specific open smart digital platform. The platform will help identify the determinants of patients’ health status, define patient profiles in a real-world context, and provide real-time recommendations. The project will thus enable better monitoring of the health and quality of life of cancer patients who are undergoing immunotherapy.

Objective

"Cancer immunotherapy brought about significant progress in cancer treatment. It resulted in high efficacy in some cancers; e.g. up to 60% objective response rate in melanoma and 80% complete response rate in acute lymphoblastic leukaemia. Nevertheless, two main challenges still impede improving cancer patients’ health status and quality of life (QoL) after immunotherapy initiation: 1) a crucial need for “predictive markers” of occurrence of immunotherapy-related adverse events (IR-AEs) to predict and improve patients’ health status and promote their QoL; and, 2) the lack of knowledge on patients after start of immunotherapy outside randomised controlled trials. To reach these goals, significantly more diversified sources of data are required.
Project QUALITOP aims at developing a European immunotherapy-specific open Smart Digital Platform and using big data analysis, artificial intelligence, and simulation modelling approaches. This will enable collecting and aggregating efficiently real-world data to monitor health status and QoL of cancer patients given immunotherapy. Through causal inference analyses, QUALITOP will identify the determinants of health status regarding IR-AEs and define patient profiles in a real-world context. For this, heterogeneous data sources (big data), both retrospective and prospective --collected for QUALITOP from clinical centres in four EU countries—will integrate lifestyle, genetic, and psychosocial determinants of QoL. Using machine learning approaches, QUALITOP will provide ""real-time"" recommendations stemming from patient profiles and feedbacks via the Smart Digital Platform. Furthermore, an increased visibility on patients’ behaviour, a better IR-AEs prediction, and an improvement of care coordination will help analysing through simulation modelling approaches the gain in cost-effectiveness. Guidelines will be issued over the short and long-term.
"

Fields of science

Keywords

Programme(s)

Topic(s)

Call for proposal

H2020-SC1-DTH-2018-2020

See other projects for this call

Sub call

H2020-SC1-DTH-2019

Funding Scheme

RIA - Research and Innovation action

Coordinator

HOSPICES CIVILS DE LYON
Net EU contribution
€ 889 375,00
Address
QUAI DES CELESTINS 3
69002 Lyon
France

See on map
Region
Auvergne-Rhône-Alpes Rhône-Alpes Rhône
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Links
Total cost
€ 889 375,00

Participants (15)

Share this page

Download

Last update: 25 March 2024

My Booklet

Permalink: https://cordis.europa.eu/project/id/875171

European Union, 2024